JCO Oncology Practice
Coverage of JCO Oncology Practice in the Nexus archive.
- GLP-1 weight-loss drugs might help protect against breast cancer, study presented at ASCO meeting suggests
A study presented at the American Society of Clinical Oncology conference suggests GLP-1 weight-loss drugs like Wegovy and Zepbound may reduce breast cancer risk by over 30% in women. The observational study analyzed health records of 111,000 women and found those prescribed GLP-1 medications had significantly lower breast cancer incidence, though researchers caution the findings do not prove causation.
- Penn study finds GLP-1 use associated with lower breast cancer risk; researchers to launch clinical trial
A University of Pennsylvania study found that women taking GLP-1 receptor agonist medications like Ozempic and Wegovy had a 30% lower risk of breast cancer compared to those who did not. Researchers plan to launch a clinical trial to confirm these findings and explore the drugs' potential to prevent cancer recurrence and improve survival rates.